SUVENPHAR2020-10-012020-12-31in-bse-fin:OneOperatingExpenses01Member SUVENPHAR2020-10-012020-12-31in-bse-fin:OneOperatingExpenses02Member SUVENPHAR2020-10-012020-12-31in-bse-fin:OneOperatingExpenses03Member SUVENPHAR2020-10-012020-12-31in-bse-fin:FourOperatingExpenses01Member SUVENPHAR2020-10-012020-12-31in-bse-fin:FourOperatingExpenses02Member SUVENPHAR2020-10-012020-12-31in-bse-fin:FourOperatingExpenses03Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares SUVENPHAR 2020-04-01 2021-03-31 2021-02-03 INR Lakhs Third quarter Single segment Contract Development and ManufacturingnOperations (CDMO) 2020-10-01 2020-12-31 Unaudited Standalone 2749332000.00 48429000.00 2797761000.00 797582000.00 0.00 -135457000.00 213471000.00 27315000.00 87575000.00 492181000.00 1482667000.00 1315094000.00 0.00 1315094000.00 344422000.00 -5676000.00 338746000.00 0.00 976348000.00 0.00 0.00 0.00 0.00 976348000.00 -2046000.00 974302000.00 0.00 0.00 254565000.00 1 3.84 3.84 0.00 0.00 3.84 3.84 1) The above unaudited financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 10th February, 2021. The above results have been subjected to limited review by the statutory auditors of the company n2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. n3) The consolidated financial results include the results of the wholly owned subsidiary Suven Pharma, Inc. and Associate Rising Pharma Holdings, Inc. n4) The Board has allotted the Bonus shares at 1:1 ratio in it's Board meeting held on 29th September, 2020. Accordingly the number of shares increased from 12,72,82,478 to 25,45,64,956. In order to maintain uniformity and comparability the EPS of previous periods have been restated. The paid-up share capital on account of Bonus issue of Rs.1272.82 Lakhs has been appropriated from share premium account. n5) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented. n6) The National Company Law Tribunal, Hyderabad Bench vide its order dated January 06, 2020 has approved the scheme of arrangement for demerger of CRAMS undertaking of the Suven Life Sciences Limited (SLSL) to Suven Pharmaceuticals Limited (SPL) with effect from October 01, 2018 (the appointed date). The Scheme became effective from October 01, 2018. Pursuant to the Scheme, all the assets, liabilities, income and expenses of the CRAMS undertaking have been transferred to SPL from the appointed date. n7) The COVID-19 did not have a major impact on the business and research operations, which includes our subsidiary, Suven Pharma, Inc. n8) Pursuant to a fire accident on 26th, April 2020 at Jeedimetla Plant, certain fixed assets and other contents in building was damaged. The company has lodged an initial estimate of loss with insurance company and survey is currently ongoing. During the period ended 31st December 2020, the company has written off net book value of assets aggregating Rs 128.80 Lakhs and recognised a minimum insurance claim receivable for equivalent amount. n9) The Board has declared in its meeting held on 10th February 2021 an Interim Dividend of Rs.1.00 per equity share (100% of face value of Rs.1.00/- each) for the financial year 2020-21. n10) The corresponding previous period figures have been regrouped / reclassified where ever necessary. Single segment 2020-04-01 2020-12-31 Unaudited Standalone 7505537000.00 109388000.00 7614925000.00 2229404000.00 0.00 -123558000.00 597203000.00 92006000.00 233211000.00 1314926000.00 4343192000.00 3271733000.00 0.00 3271733000.00 833686000.00 -3901000.00 829785000.00 0.00 2441948000.00 0.00 0.00 0.00 0.00 2441948000.00 -6135000.00 2435813000.00 0.00 0.00 254565000.00 1 9.59 9.59 0.00 0.00 9.59 9.59 Manufacturing Expenses 355128000.00 Other Expenses 110468000.00 R & D expense 26585000.00 Manufacturing Expenses 891063000.00 Other Expenses 328351000.00 R & D expense 95512000.00